Emerging Drugs for Idiopathic Pulmonary Fibrosis

Expert Opinion on Emerging Drugs - United Kingdom
doi 10.1517/14728214.2011.565049
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Informa Healthcare

Related search

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Idiopathic Pulmonary Fibrosis

2020English

Diagnostic Criteria for Idiopathic Pulmonary Fibrosis

Lancet Respiratory Medicine,The
PulmonaryRespiratory Medicine
2018English

Triple Therapy for Idiopathic Pulmonary Fibrosis

Thorax
PulmonaryRespiratory Medicine
2012English

Epigenomics of Idiopathic Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2012English

Idiopathic Pulmonary Fibrosis and Pirfenidone

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Focus on Idiopathic Pulmonary Fibrosis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2018English

Idiopathic Pulmonary Fibrosis (IPF) ― Common Practice in Poland Before the “Antifibrotic Drugs Era”

Advances in Respiratory Medicine
PulmonaryRespiratory Medicine
2017English

Investigational Approaches to Therapies for Idiopathic Pulmonary Fibrosis

Expert Opinion on Investigational Drugs
MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy